ESMO® 2025 Highlights: Presenter Vignette – Marit Ahrens

Dr. Marit Ahrens

Marit Ahrens

MD

University Hospital Frankfurt

2595MO

Exploratory analysis of chromophobe renal cell carcinoma in the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line treatment